CL2023000921A1 - Derivados de 1,2,3,4-tetrahidroquinolina como inhibidores de la activacion de yap/taz-tead - Google Patents

Derivados de 1,2,3,4-tetrahidroquinolina como inhibidores de la activacion de yap/taz-tead

Info

Publication number
CL2023000921A1
CL2023000921A1 CL2023000921A CL2023000921A CL2023000921A1 CL 2023000921 A1 CL2023000921 A1 CL 2023000921A1 CL 2023000921 A CL2023000921 A CL 2023000921A CL 2023000921 A CL2023000921 A CL 2023000921A CL 2023000921 A1 CL2023000921 A1 CL 2023000921A1
Authority
CL
Chile
Prior art keywords
yap
taz
prevention
treatment
tead
Prior art date
Application number
CL2023000921A
Other languages
English (en)
Inventor
Marchand Arnaud
CANDI Aurelie
Vanderhoydonck Bart
Versele Matthias
L Ii Gwaltney Stephen
Original Assignee
Springworks Therapeutics Inc
Univ Leuven Kath
Vib Vzw
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Springworks Therapeutics Inc, Univ Leuven Kath, Vib Vzw filed Critical Springworks Therapeutics Inc
Publication of CL2023000921A1 publication Critical patent/CL2023000921A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La presente invención se refiere a compuestos novedosos, a dichos compuestos para usar como un medicamento, mas en particular para la prevención o tratamiento de enfermedades mediadas por actividad de transcripción YAP/TAZ-TEAD, aun mas en particular para la prevención o tratamiento de cáncer o fibrosis. La presente invención también se refiere a un método para la prevención o tratamiento de dichas enfermedades que comprenden el uso de los compuestos novedosos. La presente invención además se refiere a composiciones farmacéutica o preparaciones de combinación de los compuestos novedosos así como también a dichas composiciones o preparaciones para usar como un medicamente, mas preferentemente para la prevención o tratamiento de enfermedades medidas por actividad de transcripción YAP/TAZ-TEAD, aun mas en particular para la prevención o tratamiento de cáncer o fibrosis. LA presente invención también se refiere a procesos para la preparación de dichos compuestos.
CL2023000921A 2020-09-30 2023-03-29 Derivados de 1,2,3,4-tetrahidroquinolina como inhibidores de la activacion de yap/taz-tead CL2023000921A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20199435 2020-09-30

Publications (1)

Publication Number Publication Date
CL2023000921A1 true CL2023000921A1 (es) 2023-11-24

Family

ID=72709209

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023000921A CL2023000921A1 (es) 2020-09-30 2023-03-29 Derivados de 1,2,3,4-tetrahidroquinolina como inhibidores de la activacion de yap/taz-tead

Country Status (15)

Country Link
US (1) US20240025856A1 (es)
EP (1) EP4222143A1 (es)
JP (1) JP2023544719A (es)
KR (1) KR20230113278A (es)
CN (1) CN116783165A (es)
AR (1) AR123656A1 (es)
AU (1) AU2021353009A1 (es)
CA (1) CA3194456A1 (es)
CL (1) CL2023000921A1 (es)
CO (1) CO2023005342A2 (es)
IL (1) IL301691A (es)
MX (1) MX2023003627A (es)
PE (1) PE20240017A1 (es)
TW (1) TW202229240A (es)
WO (1) WO2022072741A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023183437A1 (en) * 2022-03-22 2023-09-28 Sporos Biodiscovery, Inc. Tead inhibitors and methods of use
KR20240014034A (ko) * 2022-07-21 2024-01-31 주식회사 바오밥에이바이오 헤테로비시클릭 화합물 및 그를 포함하는 약제학적조성물
CN115181756B (zh) * 2022-08-03 2023-06-16 四川省医学科学院·四川省人民医院 一种重组慢病毒载体、重组慢病毒质粒、细胞模型及相关应用
TW202423428A (zh) 2022-09-29 2024-06-16 香港商英矽智能科技知識產權有限公司 Tead抑制劑及其使用方法
WO2024159088A1 (en) * 2023-01-27 2024-08-02 Opna Bio SA Compounds and methods for yap/tead modulation and indications therefor
WO2024159081A1 (en) * 2023-01-27 2024-08-02 Opna Bio SA Compounds and methods for yap/tead modulation and indications therefor
WO2024159067A1 (en) * 2023-01-27 2024-08-02 Opna Bio SA Compounds and methods for yap/tead modulation and indications therefor
WO2024159079A1 (en) * 2023-01-27 2024-08-02 Opna Bio SA Compounds and methods for yap/tead modulation and indications therefor
WO2024210578A1 (ko) * 2023-04-05 2024-10-10 주식회사 바오밥에이바이오 헤테로비시클릭 화합물 및 그를 포함하는 약제학적 조성물
CN117024616A (zh) * 2023-07-10 2023-11-10 张琦 一种褐藻多糖衍生物纳米胶束的制备及其应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
AU2003242250A1 (en) * 2002-06-12 2003-12-31 Sumitomo Pharmaceuticals Co., Ltd. Cyclic amine and medicinal composition containing the same
GB0320422D0 (en) 2003-08-30 2003-10-01 Astrazeneca Ab Chemical compounds
JP4932730B2 (ja) * 2004-11-24 2012-05-16 アボット・ラボラトリーズ バニロイド受容体サブタイプ１（ｖｒ１）受容体を阻害するクロマニル尿素化合物およびその使用
ATE424821T1 (de) 2004-12-02 2009-03-15 Prosidion Ltd Pyrrolopyridin-2-karbonsäureamide
US20060160850A1 (en) * 2005-01-18 2006-07-20 Chongqing Sun Bicyclic heterocycles as cannabinoid receptor modulators
WO2010116270A1 (en) 2009-04-10 2010-10-14 Pfizer Inc. Ep2/4 agonists
WO2011034741A1 (en) * 2009-09-15 2011-03-24 Merck Sharp & Dohme Corp. Imidazopyridin-2-one derivatives
WO2013188138A1 (en) 2012-06-11 2013-12-19 The Regents Of The University Of California Inhibitors of hippo-yap signaling pathway
EP3353156B1 (en) 2015-09-23 2021-11-03 The General Hospital Corporation Tead transcription factor autopalmitoylation inhibitors
WO2017058716A1 (en) 2015-09-28 2017-04-06 Vivace Therapeutics, Inc. Tricyclic compounds
EP3156404A1 (en) 2015-10-15 2017-04-19 Inventiva New compounds inhibitors of the yap/taz-tead interaction and their use in the treatment of malignant mesothelioma
MY196809A (en) 2015-12-24 2023-05-03 Kyowa Kirin Co Ltd (),()-unsaturated amide compound
WO2018185266A1 (en) 2017-04-06 2018-10-11 Inventiva New compounds inhibitors of the yap/taz-tead interaction and their use in the treatment of malignant mesothelioma.
CA3062294A1 (en) 2017-05-03 2018-11-08 Vivace Therapeutics, Inc. Non-fused tricyclic compounds
WO2018235926A1 (ja) 2017-06-23 2018-12-27 協和発酵キリン株式会社 α、β不飽和アミド化合物
CA3073543A1 (en) 2017-08-21 2019-02-28 Vivace Therapeutics, Inc. Benzosulfonyl compounds
US11524943B1 (en) 2017-12-06 2022-12-13 Vivace Therapeutics, Inc. Benzocarbonyl compounds
WO2019222431A1 (en) 2018-05-16 2019-11-21 Vivace Therapeutics, Inc. Oxadiazole compounds
CN112204029B (zh) 2018-05-31 2024-03-01 豪夫迈·罗氏有限公司 治疗性化合物
JP7535500B2 (ja) 2018-09-03 2024-08-16 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｔｅａｄモジュレーターとして有用なカルボキサミドおよびスルホンアミド誘導体
EP3632908A1 (en) 2018-10-02 2020-04-08 Inventiva Inhibitors of the yap/taz-tead interaction and their use in the treatment of cancer
EP3866798A4 (en) 2018-10-15 2022-07-13 Dana-Farber Cancer Institute, Inc. ENHANCED TRANSCRIPTIONAL ASSOCIATED DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND THEIR USES
US20210403415A1 (en) 2018-10-26 2021-12-30 The Trustees Of Indiana University Compounds and methods to attenuate tumor progression and metastasis
MX2021005314A (es) 2018-11-09 2021-08-24 Vivace Therapeutics Inc Compuestos biciclicos.
WO2020243423A1 (en) * 2019-05-31 2020-12-03 Ikena Oncology, Inc. Tead inhibitors and uses thereof

Also Published As

Publication number Publication date
AU2021353009A1 (en) 2023-06-08
CO2023005342A2 (es) 2023-08-18
JP2023544719A (ja) 2023-10-25
KR20230113278A (ko) 2023-07-28
TW202229240A (zh) 2022-08-01
IL301691A (en) 2023-05-01
AR123656A1 (es) 2022-12-28
CN116783165A (zh) 2023-09-19
PE20240017A1 (es) 2024-01-04
MX2023003627A (es) 2023-06-21
EP4222143A1 (en) 2023-08-09
CA3194456A1 (en) 2022-04-07
US20240025856A1 (en) 2024-01-25
AU2021353009A9 (en) 2024-05-23
WO2022072741A1 (en) 2022-04-07

Similar Documents

Publication Publication Date Title
CL2023000921A1 (es) Derivados de 1,2,3,4-tetrahidroquinolina como inhibidores de la activacion de yap/taz-tead
DOP2022000124A (es) Derivados de pirazolilo útiles como agentes anticancerígenos
DOP2010000013A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
DOP2010000011A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
CO6382119A2 (es) Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades
CR11200A (es) Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o p13k
ECSP19083621A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
NI201900099A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
UY31384A1 (es) Novedosos compuestos heterociclicos para la inhibicion de la proteina quinasa b
ECSP19070413A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
TR201802944T4 (tr) İlaç olarak azai̇ndazol veya di̇azai̇ndazol türünün türevleri̇
ECSP19083640A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CU20140037A7 (es) Derivados de estra- 1,3,5(10), 16- tetraen- 3- carboximida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
BR112021011325A2 (pt) Derivados de rapamicina
CL2022002975A1 (es) Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus métodos de uso
CL2019003467A1 (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias.
BR112022016124A2 (pt) Composto de di-hidronaftiridinona, e método de preparação para este e uso médico deste
AR128109A1 (es) Spiros y análogos relacionados para inhibir yap / taz-tead
UY33745A (es) Derivados de difenilamina: usos, procedimiento de síntesis y composiciones farmacéuticas
UY29640A1 (es) Amidas sustituidas con heteroarilo que comprenden un grupo enlazador saturado, y su uso como agentes farmacéuticos.
AR128110A1 (es) Tetrahidropirazolopirimidinas y análogos relacionados para la inhibición de yap / taz tead
AR069569A1 (es) Derivados de benzoxazina, un intermediario para su preparacion, una composicion farmaceutica que los comprende y su uso para la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de renina.
PA8675301A1 (es) DERIVADOS DE (SULFAMOIL-ALQUIL)-AMIDA DE ÁCIDO HETEROARIL-CARBOXÍLICO COMO INHIBIDORES DEL FACTOR Xa.
BR112023024085A2 (pt) Composto usado como inibidor de bcr-abl
BR112018001720A2 (pt) compostos de derivado de 1,3,4-oxadiazol sulfonamida como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos